Abatacept is a fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc portion of human immunoglobulin G1 (IgG1). Abatacept selectively modulates a key costimulatory signal required for full activation of T lymphocytes expressing CD28.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Abatacept is the active ingredient of these drugs:
Australia Austria Brazil Canada Cyprus
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):